Left arrow icon
Left arrow icon
Left arrow icon

We expect more for those who matter most: patients

Millions of people suffer from chronic autoimmune and inflammatory diseases. At DICE, we understand that currently available medicines for these diseases can be invasive and inaccessible.


We are Committed

to developing convenient, oral medicines for a variety of immunological conditions. We study our innovative oral therapeutics in clinical trials with the goal of making them available to patients in need as rapidly as possible.

Clinical Trials

0 1


We are conducting a Phase 1 trial with DC-853 designed to generate safety and pharmacokinetic data in healthy participants.

0 2


We have successfully completed a Phase 1 proof-of-concept trial supporting the further development of DC-806 as a potential best-in-class oral agent for psoriasis. We are conducting a dose-ranging Phase 2b clinical trial in patients with moderate-to-severe psoriasis.